Journal
MEDICAL HYPOTHESES
Volume 73, Issue 5, Pages 662-663Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.mehy.2009.04.046
Keywords
-
Categories
Funding
- National Basic Research Program (973 Project) of China [2007CB507406]
- National Natural Science Foundation of China [30572341]
- Tsinghua-Yue-Yuen Medical Sciences Fund [THYY-20070008]
Ask authors/readers for more resources
Emerging evidences indicate that elevated cholesterol and triglyceride levels precede Alzheimer's disease (AD) pathology. High caloric intake based on saturated fat raises hyperlipidaemia and also promotes AD pathology. As a result, strategy that limits the absorption of dietary fat and attenuates hyperlipidemia could be a useful medication for protective treatment of AD. As an active site-directed inhibitor of digestive lipases, orlistat effectively reduces dietary fat absorption and decreases total cholesterol and triglyceride levels in plasma. Orlistat also potently inhibits lipoprotein lipase, monoacylglycerol lipase and diacylglycerol lipase, which are also involved in AD causation. Taken together, orlistat inhibits lipases activities, thereby reduces dietary fat intake and ameliorates hyperlipidemia, which indicates a therapeutic potential of orlistat in protecting against AD pathology. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available